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ABSTRACT 
Natural products found in Mitragyna speciosa, commonly known as kratom, represent diverse 
scaffolds (indole, indolenine and spiro pseudoindoxyl) with opioid activity, providing 
opportunities to better understand opioid pharmacology. Herein, we report the pharmacology and 
SAR studies both in vitro and in vivo of mitragynine pseudoindoxyl (3), an oxidative 
rearrangement product of the corynanthe alkaloid mitragynine. 3 and its corresponding 
corynantheidine analogs show promise as potent analgesics with a mechanism of action that 
includes mu opioid receptor agonism-delta opioid receptor antagonism. In vitro, 3 and its analogs 
were potent agonists in [35S]GTPγS assays at the mu opioid receptor but failed to recruit β-
arrestin-2, which is associated with opioid side effects. Additionally, 3 developed analgesic 
tolerance more slowly than morphine, showed limited physical dependence, respiratory 
depression, constipation, and displayed no reward or aversion in CPP/CPA assays, suggesting 
that analogs might represent a promising new generation of novel pain relievers.  
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INTRODUCTION 
Opioids, including morphine, are clinically used for the treatment of moderate to severe 
chronic pain. However, despite their proven efficacy, mu opioid receptor agonists have 
problematic side effects such as tolerance, physical dependence, and substance abuse.1 Agonists 
selective for other opioid receptors produce analgesia, but with their own liabilities.2-4 The 
ultimate goal of opioid-related drug development has been to design and synthesize potent  
antinociceptive agents that are devoid of adverse side effects. Many approaches have been taken 
over the years, starting with the development of partial agonists or mixed agonist/antagonists.5-9 
A more recent approach takes advantage of biased agonism, in which distinct downstream 
signaling pathways are activated by different agonists working through the same receptor.10, 11 It 
has been proposed that ligands biased against recruiting β-arrestin-2, or showing preference for 
activating specific G-protein mediated signal transduction pathways, will demonstrate 
diminished side effects.12, 13 Oliceridine (TRV130)14, 15 is an example of a mu-opioid receptor 
biased agonist which has recently entered phase-III clinical trials, showing separation between 
antinociception and some opioid-related side effects. 6'-Guanidinonaltrindole (6’-GNTI),16 22-
thiocyanatosalvinorin A (RB-64),17 and two new classes of kappa opioid ligands from the Aube 
group have also recently been reported in the opioid literature as biased kappa opioid receptor 
agonists.18, 19  
Natural products have provided many lead compounds leading to the design of new 
pharmaceuticals. Natural products and their derivatives account for approximately 50% of 
approved drugs.20 Morphine, the most commonly employed opioid, and thebaine, the structure 
on which the vast majority of semi-synthetic opiates is based, are natural alkaloids found in the 
poppy plant, Papaver somniferum. While opioid chemistry has traditionally been dominated by 
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thebaine-derived alkaloids isolated from poppy, there are a growing number of opioid natural 
products derived from structures other than the traditional morphinan scaffold and thus  
structurally not closely related to morphine. These include analogs of salvinorin A21-23 such as 
herkinorin24 and thiocyanatosalvinorin A17, which have been developed as mu- and kappa-opioid 
receptor biased agonists, respectively, while some peptide analogs such as cyclo[Phe-d-Pro-Phe-
Trp] (CJ-15,208)25 are being developed as analgesics and medications against cocaine abuse 
(Figure 1). Mitragynine (indole core) (1) and its congeners isolated from the Southeast Asian 
plant Mitragyna speciosa, commonly known as kratom, are monoterpene indole alkaloids 
structurally not closely related to morphine.26 In addition to its traditional use, kratom has 
become a quickly emerging substance of abuse.  It is currently legal in many parts of the world, 
and kratom leaves are available for purchase over the internet. Case studies of fatalities resulting 
from overdose have been published, although the risk posed by mitragynine remains uncertain, 
given that simultaneous use or contamination with other substances (including opioids) that may 
have been involved in the reported deaths.27-30 Both mitragynine (1) and its naturally occurring 
oxidation product, 7-OH mitragynine (indolenine core) (2), are opioid antinociceptive agents that 
have been examined both in vitro and in vivo.31-39 Mitragynine pseudoindoxyl (3), a 
rearrangement product of 2 with a spiro-pseudoindoxyl core, was first isolated in 1974 by 
Zarembo et al. as a microbial metabolite of 1 by the fungus Helminthosporum sp.40 Yamamoto et 
al. reported that it acted non-selectively on mu- and delta-opioid receptors while its kappa-opioid 
receptor affinity was negligible.41 In later publications by Takayama et al., the in vivo 
supraspinal analgesic properties of 3 were briefly discussed.39  
In this work, we report the in vitro and in vivo pharmacology and structure-activity 
relationships (SAR) of mitragynine pseudoindoxyl (3). We demonstrate for the first time that 3 
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and its C-9 substituted derivatives, corynantheidine pseudoindoxyls, are systemically active 
mixed mu-opioid receptor agonist/delta-opioid receptor antagonist compounds in vitro, and 
produce potent antinociception in vivo. Characterization of 3 demonstrated opioid-mediated 
analgesia devoid of any place-conditioning effects, and a side effect profile far superior to 
clinically used mu opioid  based antinociceptive agents. 
RESULTS 
Chemistry: 
 1 was extracted from dry kratom powder using a modified protocol reported by Ponglux 
et al.42 Compounds 2 and 3 were synthesized from 1 as shown in Scheme 1.39, 43 To better 
understand the pharmacology of this template, SAR studies were carried out by modifying the C-
9 and N-1 (indole nitrogen) positions. Six analogs with various substituents in the C-9 positions 
and 2 analogs at N-1 were synthesized. C-9-substituted corynantheidine pseudoindoxyl 
derivatives were synthesized starting from 2. To gain access to the C-9 position on the 
pseudoindoxyl scaffold, 2 was converted to 9-hydroxycorynantheidine pseudoindoxyl (4) using 
AlCl3 and ethanethiol in DCM. This intermediate was converted to its triflate (5) using triflic 
anhydride and pyridine, which was subsequently used as the precursor for further reactions.  
The pseudoindoxyl of corynantheidine (6) was synthesized using palladium-catalyzed 
removal of the triflate ester by formic acid. The synthesis of the nitrile 7 was accomplished in a 
palladium-catalyzed reaction of 5 with Zn(CN)2. Compounds 8 and 9 were obtained via Suzuki 
coupling reactions of 5 and the appropriate boronic acids. 3 was alkylated in the N-1 position 
with benzyl bromide and iodomethane to synthesize 11 and 12, respectively. 
In vitro pharmacology: 
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Initial investigations used in vitro radioligand binding assays with cell lines stably 
expressing murine opioid receptors (Figure 2, Table 1). Mitragynine (1) showed poor affinity at 
all opioid receptors, whereas 7-hydroxymitragynine (2) showed moderate affinity at the mu 
opioid receptor clone MOR-1, 5-fold higher than 1, and was considerably more potent at the 
expressed delta opioid receptor clone DOR-1 than 1.44 Mitragynine pseudoindoxyl (3) displayed 
the highest overall binding affinity for MOR-1 and DOR-1 (Ki  0.8 nM and 3 nM, respectively) 
while also showing a moderate affinity for KOR-1 . These data suggest that conversion of the 
indole to indolenine ring to the spiro-pseudoindoxyl core dramatically increases affinity for 
opioid receptors. The binding affinities of 3 at MOR-1 and DOR-1 were comparable to the 
prototypic mu ligands morphine and DAMGO, and delta ligands DPDPE and NTI. Alkyl 
substitution at the N-1 position of the template (compounds 11, 12) eliminated opioid affinity, 
suggesting that the unsubstituted indole NH is important for receptor binding. Substitutions at C-
9, however, yielded potent derivatives. All six C-9-modified compounds (4, 6-9, 10) maintained 
the high affinity at both MOR-1and DOR-1 sites as observed with 3 previously.  2 and 3 were 
also screened across a panel of other non-opioid drug targets using the PDSP screening facility at 
NIMH.45 2 exhibited no affinity appreciable affinity at these receptors (Ki > 10 µM). 3 had poor 
affinity at α2A adrenergic receptor, α2C adrenergic receptor and 5HT7 (Table S1).   
In [35S]GTPγS functional assays using opioid transfected cell lines, 1 was a partial 
agonist with moderate potency at MOR-1, and a weak antagonist at both DOR-1 and KOR-1  
(Table 2). 2 was a partial agonist at MOR-1, 4-fold more potent than 1, and a weak KOR-1 and 
DOR-1 antagonist.44 Analog 3 was a potent full agonist at MOR-1 and an antagonist at both 
DOR-1 and KOR-1. Most C-9-modified derivatives (4, 6, 7 and 9) were MOR-1 agonists and 
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DOR-1 antagonists in functional assays with the exception of compound 8, which was a dual 
MOR-1/DOR-1 agonist (Table 2).  
Both DAMGO and endomorphin-2 effectively recruited β-arrestin-2 in CHO cells 
expressing MOR-1, as measured with the DiscoveRx PathHunter assay. In contrast, compounds 
1-4 and 6-9 failed to recruit β-arrestin-2 at concentrations as high as 10 µM (Figure 3A). Both 2 
and 3 reduced DAMGO-induced β-arrestin-2 stimulation in these cells in a concentration-
dependent manner (Figure 3B)44 consistent with their respective binding affinities at the receptor. 
Thus, 3 and its analogs potently stimulated [35S]GTPγS binding without stimulating β-arrestin-2 
recruitment.  However, their antagonism of DAMGO stimulation of β-arrestin-2 recruitment 
revealed that they could still bind to both G-protein and arrestin functional receptor 
configurations.  
Antinociception:  
The antinociceptive effect of mitragynine and its derivatives was evaluated in vivo in 
mice using the radiant heat tail flick assay (Table 1). After subcutaneous administration, 1 
produced antinociception with an ED50 (and 95%CI) value of 166 mg/kg (101, 283), 66-fold less 
active than morphine. On the other hand, 2 was about 5-fold more potent than morphine and 350-
fold more potent than 1 (Figure S1), similar to literature values.32-34 Compound 3 was 1.5-fold 
more potent than morphine after intracerebroventricular administration (icv, Figure 4A and S2), 
and 3-fold more potent following subcutaneous (sc, Figure 4B and S4A and S4B) administration. 
Compound 3 has a shorter duration of antinociceptive effect than morphine with a peak effect at 
15 min (Figure S3). Compound 3 proved equally active in CD1, C57BL/6 and 129Sv6 strains of 
mice subcutaneously (Figure S5). Furthermore, 3 also was active orally, with an ED50 (95% CI) 
value of 7.5 (4.3-13) mg/kg (Figure 4C). The C-9 derivatives (4 and 6-10) also produced 
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antinociception following systemic administration, with ED50 values comparable to 3 (Table 1). 
Compound 3 was also active in the hot plate assay of antinociception, with an ED50 (95% CI) 
value of 0.99 (0.75–1.3) mg/kg (Figure 4D and S4C), comparable to morphine (ED50 = 1.7 (1.3, 
2.4) mg/kg) (Figure S4D). 
Opioid receptor antagonism: 
Based on the high affinity and favorable mixed mu agonist/delta antagonist profile in 
vitro, we examined the activity of compound 3 in greater detail. Naloxone and the mu-selective 
antagonist β-FNA effectively reversed 3-induced antinociception, whereas the delta-selective 
antagonist NTI and the kappa antagonist norBNI did not. Yohimbine, an α2 antagonist, had no 
effect on the antinociception of 3 (Figure 5A). 
To examine the selectivity of antinociception further, we used an antisense 
oligodeoxynucleotide mapping paradigm. The activity of the oligodeoxynucleotide antisense 
probes for MOR-1, KOR-1 and DOR-1 has been established previously.46-48 Targeting exon 1 of 
MOR-1, the antisense oligodeoxynucleotide lowered the analgesic actions of morphine, 
reproducing earlier studies (Figure S6).46 Similarly, the responses of 3 were lowered (Figure. 
5B). The specificity of the response was established by the inactivity of the control mismatch. 
Similarly, downregulation of exon 3 of DOR-148 and exon 2 of KOR-149 with antisense 
oligodeoxynucleotides attenuated antinociception produced by the prototypic delta agonist 
DPDPE and the prototypic kappa agonist U50,488H, in accordance with previous studies (Figure 
S6). However, these oligodeoxynucleotides targeting kappa and delta receptors did not alter the 
antinociception of 3 (Figure 5B).  
The mu opioid receptor Oprm1 creates an array of splice variants through alternative 
splicing with patterns conserved from rodents to humans.50, 51 The major sets of variants are full-
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length 7 transmembrane domain (7TM) variants associated with exon 1 (E1). A second set of 
variants of truncated six transmembrane domain splice variants (6TM) is generated by an 
alternative promoter associated with exon 11 (E11) of the Oprm1 gene.52, 53 MOR-1 KO mice 
were used to establish the contributions of 7TM E1-MOR-1 and 6TM E11-MOR-1 variants to 3 
antinociception. 
Two different types of MOR-1 KO mice were utilized: exon 11 (E11) MOR-1 KO mice, 
which lack the 6TM E11splice variants of MOR-1 but retain expression of 7TM E1 splice 
variants of MOR-1, and total mu opioid receptor knockout in which both exons 1 and 11 were 
disrupted (E1/E11) to eliminate all 7TM, and 6TM mu opioid receptor variants of the Oprm1 
gene. Morphine antinociception has previously been demonstrated to be independent of the E11-
associated 6TM splice variants of MOR-1, maintaining full analgesic activity in the E11 KO54, 
but its antinociception was completely eliminated in E1/E11 MOR-1 KO mice,55 suggesting  
7TM E1-MOR-1 variant as the primary mechanism of analgesic action. Compound 3 showed 
similar antinociceptive responses as morphine.  Compound 3 antinociception was similar in 
wild-type (ED50 = 0.83 mg/kg (0.37-1.9)) and exon 11 KO C57/BL6 mice (ED50 = 1.4 mg/kg 
(0.34-5.8)) in a tail flick assay (Figure 5D). However, antinociception of compound 3 was 
eliminated in E1/E11 MOR-1 KO mice (ED50 >30mg/kg), indicating a mu opioid receptor 
mechanism.55 Taken together with the antisense results, these in vivo findings indicate that 3 
analgesia is mediated by 7TM E1-MOR-1 receptors. 
Side effect profile: 
We next evaluated 3 in mouse models of antinociceptive tolerance, dependence, 
respiratory depression, and inhibition of GI transit (Figure 6). Mice developed antinociceptive 
tolerance to morphine after twice daily administration for 5 days (5 mg/kg/injection, sc). In 
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contrast, antinociceptive tolerance to 3 developed far more slowly, with twice daily 
administration of 3 (at an equianalgesic dose as morphine) requiring 29 days instead of 5 days 
(Figure 6A). After 5 days, the morphine ED50 value was shifted 6-fold to 12.1 (7.6-19.4) mg/kg 
from 2.0 (1.2-3.3) mg/kg. In contrast, after 5 days, the ED50 value for 3 was shifted less than 2-
fold to 1.1 (0.66-2.0) mg/kg. After 29 days, the ED50 value for 3 was shifted 6-fold (4.5 mg/kg 
(2.7-7.7) mg/kg) (Figure S7). An independent sample t-test was used to test for the group 
difference between 3 and morphine on day 5. The mean difference of 53.97 %MPE between the 
two groups was found to be statistically significant (p-value<0.0001) at the 5% level of 
significance. This difference is likely to range between 42.27 and 65.67 %MPE as measured by a 
95% confidence interval. To highlight 3’s ability to sustain antinociception over repeated dosing, 
the composite areas under the curve (AUCs) were calculated using the trapezoidal rule on the 
mean response across 1 to 29 days for the 3 group, and 1 to 5 days for the morphine group, 
respectively. The AUC for the morphine group was 205.9, while for the 3 group it was 6-fold 
larger, 1239.  
Time action studies revealed that 3 has a shorter duration of action than morphine (Figure 
S3). Since the shorter duration of action of 3 led to a decreased drug exposure, we also examined 
tolerance in a different dosing paradigm in which 3 was given four times per day to provide 
similar drug exposures for morphine and 3. In this paradigm, 3 failed to show a significant 
decreased effect over 5 days, whether examined at a fixed dose over the 5 days (Figure S8A) or 
dose-response curves at Day 5 (Figure S8B). After 5 days, the ED50 value for 3 was shifted from 
0.69 (0.46, 1.0) to 1.6 (0.97-2.6) mg/kg (Figure S8C), a shift similar to that observed when 3 was 
given twice a day (ED50 = 1.1 (0.66-2.0)) on day 5 (Figure S7). 
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Physical dependence was assessed in mice treated repeatedly with 3 at twice its ED50 
dose (1.5 mg/kg) twice daily for 5, 22 or 29 days by administration of the opioid antagonist 
naloxone. Mice showed only minimal signs of withdrawal following administration of naloxone 
with 12±4.1, 13±4.4 and 14±6.0 jumps on average, respectively (Figure 6B). These values were 
not significantly different from saline but differed significantly from mice treated with morphine 
for 5 days, which showed 77±7.2 jumps (Figure 6B). In summary, compound 3 demonstrated 
limited antinociceptive tolerance and physical dependence in comparison with morphine 
following chronic administration.  
Differences in effect between 3 and morphine extended to other opioid effects. Mu 
selective agonists inhibit gastrointestinal transit, a major component of constipation. At a dose 
twice its analgesic ED50 value (5 mg/kg, sc), morphine almost totally eliminated transit (Figure 
6C). An equianalgesic dose of 3 (1.5 mg/kg, sc) also lowered gastrointestinal transit, but not 
nearly as much as morphine. The effect on GI transit plateaued, with a greater dose (4 mg/kg, sc) 
also showing no further inhibition (Figure 6C).  
Morphine dose-dependently reduced the respiratory rate in mice, with a decrease of 
approximately 30% by a dose twice its analgesic ED50 value (5 mg/kg, sc) by approximately 
50% after a higher dose corresponding to 4-fold its analgesic ED50 value.  In contrast, 3 showed 
no respiratory depression at ~twice its antinociceptive ED50 dose in C57BL/6 mice (1.2 mg/kg, 
sc). Although a higher dose (3 mg/kg, sc), transiently lowered the respiratory rate by 
approximately 15%, this was still significantly less than morphine (Figure 6D).  
Compound 3 also failed to show either rewarding or aversive behavior in a conditioned 
place preference paradigm. In this study, morphine produced significant conditioned place 
preference (CPP; F(4,180)=5.62, p=0.003; two-way ANOVA with Tukey HSD post-hoc test) and 
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U50,488H produced conditioned place aversion (CPA), but 3 demonstrated neither preference or 
aversive behavior at doses 2-fold or 5-fold its analgesic ED50 value (n.s.; Tukey HSD post hoc 
test; Figure 6E). Overall, these results demonstrate that 3 produces potent opioid receptor-
mediated antinociception both centrally and systemically, yet shows a separation of 
antinociception from some classic opioid side effects such as antinociceptive tolerance, 
dependence, and conditioned place preference. Furthermore, 3 shows a lower propensity to cause 
respiratory depression and constipation compared with the canonical opioid, morphine. 
Modeling: 
In silico docking studies were carried out to unravel potential differences in receptor 
interactions of 1-3. The results of in silico prediction of inhibitory constants are listed in Table 3 
for all three mitragynine compounds and the opioid receptors. In general, ligands of the lowest 
energy complexes were located in the binding pocket observed in the crystal structures. 
Inhibitory constants (Ki) calculated for the lowest energy complexes follow the trend observed in 
the experiments, but the range of values is much more narrow compared to experimental data, 
suggesting much lower selectivity of both the ligands and the receptors. The lowest energy 
complexes which are considered to reflect specific binding between 1-3 and the receptors are 
shown in Figures 7 and S14. These in silico Ki values reproduce experimental data with much 
higher accuracy compared to the ones calculated for the lowest energy complexes in the first 
pass, where all non-specific hits were included (for explanation, see the Methods). Receptor side 
chains in contact with the bound 1-3 are also depicted in Figure 7 and listed in Table 3. 
DISCUSSION 
Although initially described in the scientific literature as early as 1974, very little was 
known about the pharmacology of 3 prior to this study. Its chemical structure suggested it as an 
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excellent starting point for semi-synthetic diversification. Thus, we subjected 3 to detailed 
pharmacological analysis. In opioid receptor-transfected CHO cell lines, 3 had a high affinity for 
MOR-1 and DOR-1 sites with a moderate affinity at KOR-1. After subcutaneous administration, 
3 was a potent antinociceptive agent in two thermal pain models: radiant heat tail flick and hot 
plate. It was also active in the mouse tail flick assay when administered supraspinally and orally. 
We established the agonist selectivity of 3 through pharmacological and genetic approaches, 
demonstrating that its antinociception was mediated by mu opioid receptors and not kappa, delta, 
and/or α2 adrenergic receptors. Mu antagonists attenuate the antinociception but it was 
insensitive to kappa and delta antagonists. Clonidine, an α2 agonist, is a potent analgesic used for 
the treatment of various pain conditions.56 Yohimbine, an α2 antagonist did not affect the 
antinociception of 3, therefore, its antinociception is likely not related to adrenergic pathways. 
The non-reversal of analgesia also rules out a role of α2A and α2C adrenergic receptors in 
mediating analgesia of 3 although the drug had some affinity for these receptors in our initial 
screening. Antisense downregulation of E1-MOR-1 variants attenuated antinociception while 
downregulation of DOR-1 and KOR-1 failed to modify 3 antinociception. In mice lacking E11-
MOR-1 variants (E11 MOR-1 KO mice) compound 3, like morphine, still exhibited 
antinociception comparable to wild-type mice while in mice lacking all mu opioid receptor splice 
variants (E1/E11 MOR-1 KO mice), 3 antinociception was completely eliminated. The results 
from antisense and KO mice experiments implicate traditional 7TM mu opioid receptor aka E1-
MOR-1 variants in 3 antinociception.  
Of interest, 3 signaling failed to recruit β-arrestin-2 alone and antagonized both 
DAMGO-induced β-arrestin-2 recruitment and stimulation of [35S]GTPγS binding. To the best of 
our knowledge, 3 is the first example of a mixed activity mu opioid agonist/delta antagonist 
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ligand which does not recruit β-arrestin-2. Prior evidence in the literature suggests that failure to  
recruit β-arrestin-2 and delta antagonism may both be successful in separating antinociception 
from unwanted side effects. Consistent with this, 3 displayed a robust antinociceptive effect in 
mice and without conditioned place preference or aversion. Two different dosing paradigms (two 
and four times per day) revealed the slow development of tolerance and a marked decrease in 
jumping following challenge with naloxone, which is characteristic of physical dependence. 
Furthermore, 3 showed no respiratory depression at twice its analgesic ED50 dose, and far less 
constipation than morphine. 
A number of mixed mu agonist-delta antagonist ligands have been reported in the 
literature. DIPP-NH2[Ψ],
57 5′'-(4-chlorophenyl)-6,7-didehydro-4,5α-epoxy-3-hydroxy-17-
methylpyrido[2′,3′:6,7]morphinan (SoRi20411),5 and 14-alkoxy pyridomorphinans58 are potent 
delta antagonists and mu agonists which produce analgesia with reduced tolerance when given 
supraspinally. It must be noted that a majority of these studies monitored the development of 
tolerance through the accepted practice of administering the ED80 antinociceptive dose of the test 
drug twice daily for 5-7 days. The current study tested this approach even more rigorously, yet 
still found significant reductions in antinociceptive tolerance following administration of 3 for 29 
days. DIPP-NH2[Ψ] also shows no physical dependence in treated mice. 4a,9-Dihydroxy-7a-
(hydroxymethyl)-3-methyl-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-
e]isoquinolin-7(7aH)-one (UMB425),59 and the cyclic peptide analog of KSK103 (C-terminal 
Ser(β-Glc)NH2)
6 and ([Dmt1]DALDA→CH2CH2NH←TICP[Ψ]), which connects Dmt
1-DALDA 
(mu agonist) with the delta antagonist TICP[Ψ] through a spacer, also show reduced acute 
antinociceptive tolerance compared to morphine when given systemically.60 Administration of 
delta antagonists or induced downregulation of delta opioid receptors has been reported to 
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prevent morphine tolerance without sacrificing analgesic potency.61, 62 Genetic disruption of the 
opioid system led to similar observations. In DOR-1 antisense knockdown mouse models, 
tolerance and acute dependence to morphine were eliminated63 while DOR-1 knockout animals 
did not develop antinociceptive tolerance to morphine.64 The role of delta-opioid receptors in 
blocking mu opioid-mediated CPP is still unclear65. CPP is retained unchanged or abolished 
depending on assay conditions in DOR-1 KO mice, while morphine reportedly was more 
rewarding in a study with β-arrestin-2 KO mice.66 Additional study of this phenomenon should 
be possible as additional novel ligands with suitable MOR agonist/DOR antagonist activity 
profiles such as 3 become available. 
Although GPCRs are mostly studied in relation to their ability to activate G-proteins, 
these transmembrane receptors are capable of recruiting β-arrestins to initiate separate cellular 
signal transduction pathways.67 β-Arrestin-2 activation has been implicated in the mechanism of 
receptor desensitization and the occurrence of deleterious side effects.68 Similarly to G-protein 
signaling, β-arrestin-2 activation is ligand- and receptor-dependent. Different ligands are able to 
stabilize GPCRs in a variety of conformations, resulting in the differential activation (bias) of G-
protein and β-arrestin-2-mediated signaling pathways. Therefore, ligands interacting with the 
receptor do not simply have a linear effect on efficacy but also affect the functional quality of the 
downstream pathways.69 Biased signaling of opioid receptors has been studied in detail by Bohn 
and co-workers. Compared with wild-type mice, morphine displayed enhanced antinociception 
and significantly attenuated respiratory depression, and inhibition of GI transit in β-arrestin-2 
KO mice.70-72 These results suggest that a fully G-protein biased opioid ligand that does not 
activate β-arrestin-2 signaling may be able to separate antinociception from some opioid adverse 
effects. An important example of G-protein biased opioids is oliceridine, a synthetic mu agonist 
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currently in clinical trials as an alternative to morphine and fentanyl for the treatment of chronic 
pain. Oliceridine is a potent analgesic that causes less respiratory depression and constipation 
than morphine at equianalgesic doses in humans.15  
Taken together, these previous observations may explain why 3 is able to separate 
antinociception from typical opioid side effects resulting in low risk of developing tolerance 
while showing limited physical dependence, respiratory depression and inhibition of GI transit.   
However, the relative contributions of its mu agonist/delta antagonist activity and its inability to 
recruit β-arrestin-2 to this advantageous pharmacological profile are not clear.   
In order to investigate the SAR of the mitragynine pseudoindoxyl scaffold, semi-
synthetic analogs were made starting from 1 (C-9 analogs) and 3 (N-1 analogs). Receptor 
affinities were not significantly affected by modifications at the C-9 position, although 9-O-
acetylation slightly lowered mu and delta affinities. Compounds 4 & 6-9 retained high, 
subnanomolar affinity at cells expressing MOR-1 with little change in  affinity in DOR-1 cells. 
None of the derivatives stimulated β-arrestin-2 activation. According to previous literature 
reports, C-9 modifications of mitragynine altered the efficacy at mu receptors. Replacing the C-9 
methoxy group with H yields corynantheidine, a mu antagonist, whereas C-9 O-demethylation 
yields 9-OH corynantheidine, a partial agonist in in vitro assays.39, 73 According to our studies, 
the SAR of the C-9-modified pseudoindoxyl scaffold is quite distinct. Various substituents can 
be tolerated at this position, maintaining full mu agonism. Neither C-9 O-demethylation (4), nor 
the removal of the methoxy group (6) affected the efficacies at mu as 4 and 6 were mu full 
agonists. However, the activity at delta receptors is differentially affected by varying 
substituents. Compounds 4, 6, 7, 9, 10 retained delta antagonism, while the 9-phenyl analog, 8, 
was a delta agonist. 8 was a dual mu-delta agonist with similar intrinsic activity and potency at 
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both receptors. Substitution and the introduction of bulky groups at N-1 (the indoxyl nitrogen) 
were not tolerated. Both the N-benzyl (11) and N-methyl (12) derivatives showed diminished 
affinities at all three opioid receptors compared to 3. In vivo, the C-9 analogs were  active after 
systemic administration. The 9-OH derivative (4) was more potent than 3. Removal of the 
methoxy group (6)  increased analgesic potency. The analgesic potencies of the corresponding, 
C-9 mitragynine analogs (corynantheidine and 9-OH corynantheidine) is not reported in the 
literature. These results, in addition to the in vitro data, suggest that the SAR of compounds of 
the pseudoindoxyl scaffold differs from that of the natural Mitragyna alkaloids. Substitution of 
the C-9 methoxy group with –CN, phenyl and furan-3-yl groups afforded products (7-9, 
respectively) roughly equipotent to 3. Acetylation of 4 had a slightly negative impact on the 
analgesic potency (10). 
In comparison to the mu opioid receptor-bound morphinans74-76, in silico modeling 
suggests the mitragynine derivatives (1-3) are likely to have a different binding pose. The salt 
bridge between Asp147 and the tertiary amine of the ligand and the participation of the phenolic 
OH in a water molecule assisted hydrogen bonded polar network of Tyr148, Lis233 and His297 
were described as the main, conserved interactions between morphinan ligands and the binding 
pocket.77 The presence of a salt bridge between Asp147 and the tertiary amine of 1 and its 
derivatives was a filtering criterion of docking results, therefore, it is present in the docked 
complexes of all three mitragynine compounds. The β-methoxy acrylate moiety in the 
mitragynine compounds docked in the mu receptor pocket occupied the same space as the phenol 
moiety of the morphinan scaffold in the crystallographic structures.75, 77 
The main difference between the mu receptor-bound 1, 2 and 3 is that the oxidation 
products (2 and 3) seem to participate in the polar network formed between Tyr148, Lys233 and 
Page 16 of 64
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
His297 by contributing their methoxy (C-9) and methyl ester groups and replacing H-bond 
assisting water molecules observed in the crystal structure of the agonist-bound mu receptor 
(Table 3).76 On the other hand, the beta-methoxy methyl acrylate moiety of 1 forms polar 
interactions with Gln124 and Tyr128 and do not take part in the aforementioned polar network 
(Figure S9 and Table 3). In addition to the salt bridge between Asp147 in the mu receptor crystal 
and the tertiary amine, it seems that there is a hydrogen bond present, formed with the 7-OH 
group of 2 (Figure S10). There is no significant difference in the relative orientation between the 
receptor-bound 2 and 3 (Figure S11). Differences in the calculated binding free energies and Ki 
values are most likely to emerge from the type and number of receptor contacts formed by these 
two compounds in those particularly similar docked orientations. Such differences in interactions 
are possibly due to the different heterocyclic scaffolds of  2 and 3. Compared to its derivatives, 1 
adopts a different orientation when bound to the delta receptor and forms fewer contacts with the 
residues constituting the binding pocket, resulting in a loss of affinity for this receptor. 
Admittedly, the relative orientation and the number and type of contacts formed between 2 and 3 
with the delta receptor and the calculated in silico Ki values are highly similar, rendering it 
difficult to give an accurate explanation for the one order of magnitude difference in the 
experimentally determined binding affinities. A key difference between the two bound 
geometries is that the beta-methoxy methyl acrylate moiety of 2 is positioned in a hydrophobic 
environment of Ile277, Leu300, and Ile304, (Figure S12 and Table 3) while in the case of 3 this 
group is projected into a more hydrophilic part of the binding pocket lined with Asn131, Trp274, 
and His278 (Figure S13). Furthermore, the 7-OH group of 2 was found to interact with Asp128 
(Figure S12) similarly to that observed when docked to the mu (Figure S10). In addition, the 9-
methoxy group of 2 formed contact with the phenolic OH of Tyr129. In the delta-bound 3 
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complex, both the 9-methoxy group and the carbonyl group of the pseudoindoxyl moiety were 
calculated to be in favorable position for H-bonding with Tyr129 (Figure 7 and S13). 
CONCLUSIONS 
In summary, we report for the first time the detailed in vitro and in vivo studies on 
mitragynine pseudoindoxyl. Mitragynine pseudoindoxyl is a mu agonist/delta antagonist opioid 
with a signaling bias for G-protein-mediated signaling pathways in vitro, and which produced 
potent antinociception in vivo. Perhaps owing to its mixed mu agonism/delta antagonism activity, 
mitragynine pseudoindoxyl may avoid some of the major problems of opioid therapy as we 
observed no reward or aversion, and diminished antinociceptive tolerance, physical dependence, 
respiratory depression, and GI transit inhibition in mouse models. Upon chemical modification 
of this scaffold, key SAR features distinct from the mitragynine template were revealed. Among 
analogs modified at the C-9 position, compounds with differential efficacies within in vitro 
functional assays and improved in vivo potencies were identified. Docking studies to opioid 
receptors revealed the characteristic binding modes of mitragynine-type derivatives. It is hoped 
that these studies will contribute to improved understanding of the mechanism of action of 
compounds related to mitragynine, while holding the promise to provide novel antinociceptive 
drug candidates based on the mitragynine/corynantheidine pseudoindoxyl template that separate 
antinociception from the potential for abuse and other side effects due to their unique 
pharmacological properties. Observations reported in this paper and past studies on opioid 
ligands suggest a dual mechanism (mu agonism/delta antagonism coupled with β-arrestin2- non-
recruitment) which may account for the separation of side effects from antinociception seen with 
this template. The potential contributions from each of these two mechanisms will be explored in 
future studies on this template. 
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EXPERIMENTAL SECTION 
Drugs and Chemicals: Opiates were provided by the Research Technology Branch of the 
National Institute on Drug Abuse (Rockville, MD). IBNtxA and [125I]BNtxA were synthesized in 
our laboratory as previously described.78-80 Na125I and [35S]GTPγS were purchased from Perkin-
Elmer (Waltham, MA). Selective opioid antagonists were purchased from Tocris Bioscience. 
Miscellaneous chemicals and buffers were purchased from Sigma-Aldrich. Kratom “Red 
Indonesian Micro Powder” was purchased from Moon Kratom (Austin, TX). 
 
Mice: Male CD1 mice (20-32 g) were obtained from Charles River Laboratories, C57BL/6J 
mice (20–32 g each) were obtained from Jackson Laboratories (Bar Harbor, ME). Exon-11 KO79 
and Exon-1/Exon-11 KO mice55 were bred in our laboratory. All mice used throughout the 
manuscript were opioid naïve. All mice were maintained on a 12-hour light/dark cycle with 
Purina rodent chow and water available ad libitum, and housed in groups of five until testing. All 
animal studies were preapproved by the Institutional Animal Care and Use Committees of the 
Memorial Sloan Kettering Cancer Center or University of Florida, in accordance with the 2002 
National Institutes of Health Guide for the Care and Use of Laboratory Animals. 
 
Radioligand Competition Binding Assays: [125I]IBNtxA binding was carried out in  
membranes prepared from Chinese Hamster Ovary (CHO) cells stably expressing murine clones 
MOR-1, DOR-1, and KOR-1, as previously described.7-9, 80 Binding was performed at 25°C for 
90 min. Binding in MOR-1/CHO was carried out in 50 mM potassium phosphate buffer with 5 
mM MgSO4 and 20 µg/ml protein while binding in KOR-1/CHO and DOR-1/CHO was carried 
out in 50 mM potassium phosphate pH=7.0 buffer and 40 µg/ml protein. After the incubation, 
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the reaction was filtered through glass-fiber filters (Whatman Schleicher & Schuell, Keene, NH) 
and washed three times with 3 mL of ice-cold 50 mM Tris-HCl, pH 7.4, on a semiautomatic cell 
harvester. Nonspecific binding was defined by the addition of levallorphan (8 µM) to matching 
samples and was subtracted from total binding to yield specific binding. Ki values were 
calculated by nonlinear regression analysis (GraphPad Prism, San Diego, CA). Protein 
concentrations were determined using the Lowry method with BSA as the standard.81  
 
[
35
S]GTPγS Functional Assay: [35S]GTPγS binding was performed on membranes prepared 
from transfected cells stably expressing opioid receptors in the presence and absence of the 
indicated compound for 60 min at 30 °C in the assay buffer (50 mM Tris-HCl, pH 7.4, 3 mM 
MgCl2, 0.2 mM EGTA, and 10 mM NaCl) containing 0.05nM [
35S]GTPγS; 2 µg/ml each 
leupeptin, pepstatin, aprotinin, and bestatin; and 30µM GDP, as previously described.82 After the 
incubation, the reaction was filtered through glass fiber filters (Whatman Schleicher & Schuell, 
Keene, NH) and washed three times with 3 mL of ice-cold buffer (50 mM Tris-HCl, pH 7.4) on a 
semi-automatic cell harvester. Filters were transferred into vials with 3 mL of Liquiscint 
(National Diagnostics, Atlanta, GA), and the radioactivity in vials was determined by 
scintillation spectroscopy in a Tri-Carb 2900TR counter (PerkinElmer Life and Analytical 
Sciences). Basal binding was determined in the presence of GDP and the absence of drug. Data 
was normalized to 1000 nM DAMGO, DPDPE, and U50,488 for MOR-1, DOR-1 and KOR-1 
binding, respectively. EC50, IC50, and %Emax values were calculated by nonlinear regression 
analysis (GraphPad Prism, San Diego, CA).  
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β-arrestin-2 Recruitment Assay:  β-arrestin-2 recruitment was determined using the 
PathHunter enzyme complementation assay (DiscoveRx. Fremont, CA) using modified MOR-1 
expressed in CHO cells (DiscoveRx). Cells were plated at a density of 2500 cells/well in a 384-
well plate as described in the manufacturer’s protocol. The following day, cells were treated with 
the indicated compound for 90 minutes at 37 °C followed by incubation 
with PathHunter detection reagents for 60 minutes. Chemiluminescence was measured with an 
Infinite M1000 Pro plate reader (Tecan, Männedorf, Switzerland). For the antagonist dose 
response assay, the cells were incubated with the antagonist for 30 minutes at 37 °C prior to the 
addition of agonist. Following antagonist treatment, the cells were treated with 10µM DAMGO 
for 90 minutes at 37°C and chemiluminescence was detected using the PathHunter detection 
reagents. 
 
Antinociception: Tail flick antinociception was determined using the radiant heat tail flick 
technique using an Ugo Basile model 37360 instrument as previously described.8, 9 The intensity 
was set to achieve a baseline between 2 and 3 seconds. Baseline latencies were determined 
before experimental treatments for all mice. Tail flick antinociception was assessed quantally as 
a doubling or greater of the baseline latency, with a maximal 10 second latency to minimize 
damage to the tail. Data were analyzed as percent maximal effect, %MPE, and was calculated 
according to the formula: % MPE [(observed latency − baseline latency)/(maximal latency − 
baseline latency)] x 100. Compounds were injected subcutaneously (s.c.) or 
intracerebroventricularly (i.c.v.), and antinociception was assessed 15 min later at the peak 
effect. Intracerebroventricular dosing (i.c.v.) was carried out as previously described.83 Briefly, 
the mice were anesthetized with isoflurane. A small incision was made, and synthetic opiate 
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analog (2 ul/mouse) was injected using a 10 uL Hamilton syringe fitted to a 27-gauge needle. 
Injections were made into the right lateral ventricle at the following coordinates: 2 mm caudal to 
bregma, 2 mm lateral to sagittal suture, and 2 mm in depth. Mice were tested for antinociception 
15 minutes post injection. For oral (p.o.) studies, mice were fasted for 18 h with access to water 
before administering the drug by oral gavage. For the antagonism studies β-FNA (40 mg/kg, s.c.) 
and norbinaltorphimine (norBNI, 10 mg/kg, s.c.) were administered 24 hours before 3. 
Naltrindole (NTI, 0.5 mg/kg, s.c.) was administered 15 min before 3. Antinociception also was 
assessed using the hot plate test.54 The hot plate (Ugo Basile 35100) consisted of a metal surface 
(55 °C) with a transparent plexiglass cylinder to contain the mouse. The latency to lick a hind 
paw or shake/flutter when the mouse was placed on the hot plate was measured, with a maximal 
latency of 30 seconds to avoid tissue damage. Baseline latencies were taken for each mouse prior 
to any drug administration. Mice were tested for analgesia with cumulative subcutaneous doses 
of the drug until the mouse can withstand the maximal latency. Once the mouse reached the 
maximal latency, the mouse was no longer given higher doses. In vivo experiments were 
evaluated using GraphPad Prism, San Diego, CA as described above. 
 
Antisense Assays: Antisense (AS) and mismatch (MIS) oligodeoxynucleotides were designed 
based on the published sequences of the mouse mu opioid receptor gene (Oprm1), delta opioid 
receptor gene (Oprd1), and kappa opioid receptor gene (Oprk1) (Table 3). These probes have 
been previously described and validated.49, 84-86 Antisense oligodeoxynucleotide injection: 
Groups of mice received the stated antisense by icv administration (5-10 µg) or mismatch (5-10 
µg) oligodeoxynucleotide i.c.v. under light isoflurane anesthesia on days 1, 3 and 5, as 
previously described.85 Tail flick antinociception was tested on day 6. Control groups received 
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no injection prior to testing. On test day, mice received 3 (1.5 mg/kg, s.c.), morphine (0.75 µg, 
i.c.v.), DPDPE (10 µg, i.c.v.), or U50,488H (5 mg/kg, s.c.). All experiments were performed 3 
times with similar results observed with each determination. 
 
Table 4. Sequences of Antisense (AS) and mismatch (MIS) oligodeoxynucleotides. 
Target Antisense Mismatch Control 
MOR-1 exon 1 CGCCCCAGCCTCTTCCTCT  CGCCCCGACCTCTTCCCTT  
DOR-1 exon 3 AGGGGAAGGTCGGGTAGG GAGGAGAGGTGCGTGGAG 
KOR-1 exon 2 CGCCCCAGCCTCTTCCTCT CTCCGCGCTCTCACCCTCT 
 
Respiratory Depression Assessment: Respiratory rate was assessed in awake, freely moving, 
adult male C57BL/6 mice with the MouseOx pulse oximeter system (Starr Life Sciences) as 
described previously.79 Each animal was habituated to the device for 30 min and then tested. A 
5-s average breath rate was assessed at 5-min intervals. A baseline for each animal was obtained 
over a 25-min period before drug injection, and testing began at 15 min post-injection and 
continued for a period of 35 min. Groups of mice (n = 5) were treated s.c. with either morphine 
(5 or 10 mg/kg) or 3 (1.2 or 3 mg/kg). Groups were compared with repeated-measures ANOVA 
followed by Tukey’s multiple-comparison test. 
GI transit: Gastrointestinal transit was determined as previously described.87 Animals received 
the indicated drug followed by a charcoal meal (2.5% gum tragacanth in 10% activated charcoal 
in water) by gavage. Animals were sacrificed 30 min later, and the distance traveled by charcoal 
was measured. Significance was determined by ANOVA followed by Tukey’s multiple-
comparison test.  
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Conditioned Place Preference/Aversion: Mice were conditioned with a counterbalanced place 
conditioning paradigm using similar timing as detailed previously.8 The amount of time subjects 
spent in each of three compartments was measured over a 30 min testing period.  Prior to place 
conditioning, the animals (n=95) did not demonstrate significant differences in their time spent 
exploring the left (543 ± 13 s) vs. right (571 ± 12 s) compartments (p = 0.15; Student’s t-test), 
resulting in a combined preconditioning response of -0.1 ± 19 s. During each of the next two 
days, mice were administered vehicle (0.9% saline) and consistently confined in a randomly 
assigned outer compartment for 40 min, half of each group in the right chamber, half in the left 
chamber. Four h later, mice were administered morphine (10 mg/kg, i.p.), U50,488H (30 mg/kg, 
i.p.), cocaine (10 mg/kg, i.p.), or 3 (1.3 or 3.2 mg/kg, i.p.) and confined to the opposite 
compartment for 40 min. Conditioned place preference data is presented as the difference in 
time spent in drug- and vehicle-associated chambers, and were analyzed via repeated measures 
two-way ANOVA with the difference in time spent on the treatment- vs. vehicle-associated side 
as the dependent measure and conditioning status as the between-groups factor. Where 
appropriate, Tukey’s HSD or Sidak’s multiple comparison post-hoc tests were used to assess 
group differences. Effects were considered significant when p < 0.05. All effects are expressed 
as mean ± SEM. 
 
In silico docking. Full sequence target structures of the human mu opioid and delta opioid 
receptors for docking studies were built and used as described elsewhere9, using crystal 
structures of the homologous murine opioid receptors74, 75 as templates (PDB codes: 4DKL and 
4EJ4, respectively. The x-ray structure of the human kappa receptor (PDB code: 4DJH)88 was 
used as docking target after missing side chains were added. Dockings were performed with the 
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Autodock 4.2 software. Side chains in contact with the bound ligands observed in the crystal 
complexes of the mu, delta and kappa opioid receptors were kept flexible as well as all ligand 
torsions. Mitragynine and its natural derivatives were docked using the Lamarckian genetic 
algorithm in an 80 Å x 80 Å x 80 Å grid volume with 0.375 Å spacing.  This docking volume is 
large enough to cover the whole receptor region accessible from the extracellular side. (Figure 
S14) In this sense, blind docking studies were performed and 1000 dockings were done for all 
compounds and receptor models. The resultant ligand-receptor complexes were clustered and 
ranked according to the corresponding binding free energies, which were also used to calculate 
inhibitory constants according to the following equation: ∆G = RT ln Ki. 
Chemistry 
General Methods: All chemicals were purchased from Sigma-Aldrich Chemicals, and were 
used without further purification. Reactions were carried out in flame-dried reaction flasks under 
Ar. Reaction mixtures were purified by Silica Flash chromatography on E. Merck 230–400 
mesh silica gel 60 using a Teledyne ISCO CombiFlash Rf instrument with UV detection at 280 
and 254 nm. RediSep Rf silica gel normal phase columns were used. The yields reported are 
isolated yields. IR spectra were recorded on a Bruker Optics Tensor 27 FTIR spectrometer with 
peaks reported in cm–1. NMR spectra were recorded on Bruker Avance III 500, Avance III 600 
with DCH CryoProbe instruments. NMR spectra were processed with MestReNova software 
(ver. 10.0.2.). Chemical shifts are reported in parts per million (ppm) relative to residual solvent 
peaks rounded to the nearest 0.01 for proton and 0.1 for carbon (CDCl3 
1H: 7.26, 13C: 77.3; 
CD3OD 
1H: 3.31, 13C: 49.0; DMSO-d6 
13C: 39.5). Peak multiplicity is reported as follows: s – 
singlet, d – doublet, t – triplet, q – quartet, m – multiplet. Coupling constants (J) are expressed in 
Hz. Mass spectra were obtained at the MSKCC Analytical Core Facility on a Waters Acuity 
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SQD LC-MS by electrospray (ESI) ionization. High-resolution mass spectra were obtained on a 
Waters Acuity Premiere XE TOF LC-MS by electrospray ionization. Accurate masses are 
reported for the molecular ion [M+H]+. Purity (≥95%) was confirmed using HPLC: Waters 1525 
Binary Pump, Waters 2489 UV/vis Detector, Waters XBridge C18 column (5µm x 150 x 4.6 
mm), mobile phase: solvent A: water with 0.1% TFA; solvent B: acetonitrile with 0.1% TFA. 
Gradient: 5-95% acetonitrile/water. Flow rate: 1ml/min.  
Isolation of mitragynine (1) from Mitragyna speciosa (kratom): Kratom “Red Indonesian 
Micro Powder” was purchased from Moon Kratom (Austin, TX). Mitragynine (1) was extracted 
from the powdered leaves by a modified method (added new step: petroleum ether extraction of 
the acidic aqueous phase) from that reported by Ponglux et al.42 Kratom powder (450 g) was 
extracted by refluxing with MeOH (5 x 500 mL) for 40 min. The suspension was filtered after 
each extraction and the solvent evaporated. The residue was resuspended in 20% acetic acid 
solution (2 L) and rinsed with petroleum ether (3 x 500 mL). The aqueous layer was then cooled 
on ice bath and basified (pH ~ 9) with 50% aqueous NaOH solution. The basified suspension 
was extracted with DCM (4 x 1 L). The combined organic layers were dried over Na2SO4 and 
filtered. The solvent was evaporated and the residue purified using flash column 
chromatography (gradient: 0-50% EtOAc in hexanes). The major constituent was 1 (yield 
5.59±0.59 g (1.24%); smaller quantities of speciogynine and paynantheine were also isolated. 
(E)-Methyl-2-((2S,3S,12bS)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-
a]quinolizin-2-yl)-3-methoxyacrylate (Mitragynine, 1): IR (NaCl): 3363, 2950, 2796, 1698, 
1643, 1570, 1508, 1435, 1310, 1275, 1255, 1148, 1106, 769, 734. 1H NMR (600 MHz, 
Chloroform-d) δ 7.74 (s, 1H), 7.43 (s, 1H), 6.99 (t, J = 7.9 Hz, 1H), 6.90 (d, J = 8.0 Hz, 1H), 
6.45 (d, J = 7.7 Hz, 1H), 3.87 (s, 3H), 3.72 (s, 3H), 3.71 (s, 3H), 3.18 – 3.08 (m, 2H), 3.06 – 
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2.99 (m, 2H), 3.00 – 2.93 (m, 1H), 2.94 – 2.90 (m, 1H), 2.57 – 2.42 (m, 3H), 1.83 – 1.75 (m, 
2H), 1.62 (dt, J = 11.5, 3.2 Hz, 1H), 1.24 – 1.16 (m, 1H), 0.87 (t, J = 7.4 Hz, 3H). 13C NMR 
(151 MHz, CDCl3) δ 169.45, 160.75, 154.69, 137.41, 133.90, 121.98, 117.82, 111.67, 108.03, 
104.37, 99.91, 61.74, 61.46, 57.94, 55.52, 53.98, 51.57, 40.87, 40.12, 30.14, 24.14, 19.28, 13.07. 
HRMS calcd for C23H30N2O4 (MH+), 399.2284; found 399.2285. 
(E)-Methyl-2-((2S,3S,7aS)-3-ethyl-7a-hydroxy-8-methoxy-1,2,3,4,6,7,7a,12b-octahydro 
indolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate (7-OH mitragynine, 2): Mitragynine (1, 
2.00 g, 5.02 mmol) was dissolved in acetonitrile (150 mL), then water (50 mL) was added. The 
resulting suspension was cooled to 0 °C, and the following solution was added slowly over the 
course of several minutes: PIFA (2.16 g, 1.1 equiv) in 22 mL acetonitrile. The reaction mixture 
was stirred at 0 °C for 1 hour, then saturated aqueous NaHCO3 solution was added and the 
mixture extracted with EtOAc. The organic phase was rinsed with brine (60 mL), dried over 
anhydrous Na2SO4, and then it was evaporated under reduced pressure. The residue was 
dissolved in DCM and purified using flash column chromatography (gradient: 0-75% EtOAc in 
hexanes). The fractions containing the product were evaporated to yield 1075 mg (57%) of 2 as 
a light brown amorphous powder. IR (NaCl): 3436, 2952, 1702, 1645, 1599, 1487, 1461, 1436, 
1270, 1246, 1145, 1078, 795, 738. 1H NMR (600 MHz, Chloroform-d) δ 7.44 (s, 1H), 7.34 (t, J 
= 8.0 Hz, 1H), 7.24 (d, J = 7.6 Hz, 1H), 6.78 (d, J = 8.3 Hz, 1H), 3.91 (s, 3H), 3.80 (s, 3H), 3.70 
(s, 3H), 3.31 (dd, J = 11.1, 2.6 Hz, 1H), 3.03 (ddt, J = 11.5, 5.5, 2.8 Hz, 2H), 2.84 – 2.75 (m, 
3H), 2.67 (ddd, J = 12.3, 4.3, 2.6 Hz, 1H), 2.53 – 2.46 (m, 1H), 1.98 – 1.93 (m, 1H), 1.87 (ddd, J 
= 14.6, 12.2, 4.3 Hz, 1H), 1.70 – 1.54 (m, 3H), 1.26 – 1.23 (m, 1H), 0.81 (t, J = 7.3 Hz, 3H). 13C 
NMR (151 MHz, CDCl3) δ 181.25, 169.44, 160.94, 156.02, 154.67, 131.50, 126.24, 114.46, 
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111.38, 109.65, 69.62, 62.00, 60.73, 58.32, 55.92, 51.54, 50.39, 40.67, 39.32, 36.22, 26.38, 
19.10, 13.02. HRMS calcd for C23H30N2O5 (MH+), 415.2233; found 415.2248. 
(E)-Methyl-2-((1'S,6'S,7'S)-6'-ethyl-4-methoxy-3-oxo-3',5',6',7',8',8a'-hexahydro-2'H-
spiro[indoline-2,1'-indolizine]-7'-yl)-3-methoxyacrylate (Mitragynine pseudoindoxyl, 3): 7-
OH-mitragynine (2, 200 mg, 0.48 mmol) was dissolved in dry toluene (6 mL) and Zn(OTf)2 
(350 mg, 2 equiv) was added. The reaction was stirred in a sealed tube for 2 hrs at 110 °C. To 
the cooled mixture was added 10 mL sat. aqueous NaHCO3 solution and water (20 mL). 
Extracted with EtOAc (30 mL). The organic layer was rinsed with brine (20 mL) and dried over 
anhydrous Na2SO4. After evaporation of the solvent under reduced pressure, the residue was 
redissolved in DCM and purified using flash column chromatography (gradient: 1-5% MeOH in 
DCM) to yield: 78 mg (39%) of 3 as a yellow amorphous powder. NMR was identical to that 
reported in the literature.39 IR (NaCl): 3350, 2947, 2794, 1687, 1615, 1502, 1343, 1269, 1246, 
1148, 1079, 757. 1H NMR (600 MHz, Chloroform-d) δ 7.32 (t, J = 8.1 Hz, 1H), 7.27 (s, 1H), 
6.40 (d, J = 8.1 Hz, 1H), 6.13 (d, J = 8.1 Hz, 1H), 5.13 (s, 1H), 3.89 (s, 3H), 3.66 (s, 3H), 3.62 
(s, 3H), 3.15 – 3.07 (m, 2H), 2.76 (dt, J = 11.9, 3.5 Hz, 1H), 2.38 – 2.29 (m, 2H), 2.29 – 2.18 
(m, 1H), 2.14 (dt, J = 10.2, 6.3 Hz, 1H), 1.93 – 1.84 (m, 1H), 1.63 (dt, J = 11.3, 6.8 Hz, 1H), 
1.49 (d, J = 11.3 Hz, 1H), 1.18 (ddd, J = 13.2, 7.8, 2.9 Hz, 1H), 1.11 (dd, J = 11.3, 3.6 Hz, 1H), 
0.84 (t, J = 7.4 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 199.73, 169.05, 162.27, 160.40, 158.74, 
138.85, 111.85, 109.96, 103.95, 99.21, 75.37, 73.38, 61.61, 55.86, 54.96, 53.35, 51.36, 40.28, 
38.57, 35.25, 23.95, 19.47, 13.11. HRMS calcd for C23H30N2O5 (MH+), 415.2233; found 
415.2216. 
(E)-Methyl-2-((1'S,6'S,7'S)-6'-ethyl-4-hydroxy-3-oxo-3',5',6',7',8',8a'-hexahydro-2'H-
spiro[indoline-2,1'-indolizine]-7'-yl)-3-methoxyacrylate (9-OH-corynantheidine 
Page 28 of 64
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
pseudoindoxyl, 4): 7-OH mitragynine (2, 400 mg, 0.97 mmol) was dissolved in dry DCM (20 
mL), then AlCl3 (1.29 g, 10 equiv) was added. The mixture was cooled to °0 C and ethanethiol 
(1.39 mL, 20 equiv) was added. The mixture was stirred at rt for 5 hr. Water (30 mL) was slowly 
added, then it was separated from the organic layer. The organic layer was rinsed with brine (30 
mL), then separated and dried over Na2SO4. Evaporated under reduced pressure. The residue was 
redissolved in DCM and purified using flash column chromatography (gradient: 1-3% MeOH in 
DCM) to yield 342 mg (89%) of 4 as a bright yellow amorphous powder. IR (NaCl): 3211, 2945, 
1697, 1628, 1513, 1451, 1348, 1247, 1148, 1120, 1082, 744. 1H NMR (600 MHz, CDCl3) δ 7.29 
(m, 2H), 6.30 (d, J = 8.1 Hz, 1H), 6.15 (d, J = 8.0 Hz, 1H), 5.12 (s, 1H), 3.67 (s, 3H), 3.63 (s, 
3H), 3.17 – 3.11 (m, 2H), 2.83 – 2.75 (m, 1H), 2.36 – 2.29 (m, 2H), 2.26 – 2.20 (m, 2H), 2.14 
(dd, J = 11.2, 2.8 Hz, 1H), 1.98 – 1.90 (m, 1H), 1.69 – 1.57 (m, 2H), 1.51 (d, J = 11.2 Hz, 1H), 
1.24 – 1.16 (m, 1H), 1.14 – 1.08 (m, 1H), 0.86 (t, J = 7.4 Hz, 3H). 13C NMR (151 MHz, CDCl3) 
δ 203.60, 169.03, 160.52, 160.05, 157.31, 140.24, 111.63, 108.97, 103.68, 102.27, 75.49, 72.99, 
61.69, 54.93, 53.32, 51.41, 40.21, 38.63, 34.79, 23.97, 19.43, 13.07. HRMS calcd for 
C22H28N2O5 (MH+), 401.2076; found 401.2068. 
(E)-Methyl-2-((1'S,6'S,7'S)-6'-ethyl-3-oxo-4-(trifluoromethylsulfonyloxy)-3',5',6',7',8',8a'-
hexahydro-2'H-spiro[indoline-2,1'-indolizine]-7'-yl)-3-methoxyacrylate (9-O-trifluoro 
methane sulfonyl corynantheidine pseudoindoxyl, 5): 4 (200 mg, 0.5 mmol) was dissolved in 
dry DCM (15 mL) and pyridine (647 uL, 16 equiv) was added. Then the solution was cooled to -
40 °C on a dry ice acetone bath, and the following solution was slowly added over 2-3 minutes: 5 
mL DCM and triflic anhydride (340 uL, 4 equiv). The reaction was stirred for 1h at -40 °C. After 
warming up to rt, the solution was purified using flash column chromatography without 
immediately (gradient: 20-75 % EtOAc in hexanes) to yield 233 mg (83%) of 5 as a brown 
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amorphous solid. 1H NMR (600 MHz, CDCl3) δ 7.41 (t, J = 8.1 Hz, 1H), 7.29 (s, 1H), 6.84 (d, J 
= 8.3 Hz, 1H), 6.52 (d, J = 7.9 Hz, 1H), 5.58 (s, 1H), 3.68 (s, 3H), 3.63 (s, 3H), 3.15 (d, J = 9.7 
Hz, 2H), 2.80 (dd, J = 12.5, 3.5 Hz, 1H), 2.35 (d, J = 7.4 Hz, 2H), 2.27 (d, J = 8.8 Hz, 2H), 2.18 
– 2.13 (m, 1H), 1.66 – 1.58 (m, 1H), 1.52 (d, J = 10.9 Hz, 1H), 1.22 – 1.16 (m, 2H), 0.85 (t, J = 
7.3 Hz, 4H). 13C NMR (151 MHz, CDCl3) δ 198.15, 171.40, 168.92, 161.46, 160.55, 145.34, 
138.13, 111.73, 110.01, 73.58, 61.69, 60.62, 54.84, 53.65, 53.33, 51.38, 40.14, 38.33, 35.12, 
23.84, 21.28, 19.41, 14.41, 13.00. HRMS calcd for C23H27F3N2O7S (MH+), 533.1569; found 
533.1547. 
(E)-Methyl-2-((1'S,6'S,7'S)-6'-ethyl-3-oxo-3',5',6',7',8',8a'-hexahydro-2'H-spiro[indoline-
2,1'-indolizin]-7'-yl)-3-methoxyacrylate (Corynantheidine pseudoindoxyl, 6): 5 (10 mg, 
0.019 mmol) was dissolved in dry DMF (500 uL) in a sealed tube and the following reagents 
were added: Pd(OAc)2 (1.4 mg, 0.3 equiv), dppp (4 mg, 0.5 equiv), triethylamine (52.4 uL, 20 
equiv) and formic acid (1 uL, 1.8 equiv). The mixture was stirred at 60 °C for 1h. The reaction 
mixture was diluted with EtOAc (10 mL) and washed with brine (5 mL) 5 times. The organic 
layer was dried over Na2SO4 and evaporated under reduced pressure. The residue was 
redissolved in DCM and purified using preparative TLC (75% EtOAc in hexanes) to yield 4 mg 
(57%) of 6 as an amorphous solid. IR (NaCl): 3286, 2927, 2360, 1676, 1620, 1437, 1248, 1200, 
1138, 755. 1H NMR (600 MHz, CDCl3) δ 7.55 (d, J = 7.7 Hz, 1H), 7.43 – 7.38 (m, 1H), 7.27 (d, 
J = 6.7 Hz, 1H), 6.85 (d, J = 8.3 Hz, 1H), 6.77 – 6.72 (m, 1H), 5.20 (s, 1H), 3.66 (s, 3H), 3.62 (s, 
3H), 3.20 – 3.12 (m, 2H), 2.82 – 2.76 (m, 1H), 2.38 – 2.29 (m, 2H), 2.25 (s, 2H), 2.20 – 2.13 (m, 
1H), 1.97 – 1.89 (m, 1H), 1.69 – 1.61 (m, 1H), 1.55 – 1.48 (m, 1H), 1.23 – 1.17 (m, 1H), 1.05 (s, 
1H), 0.86 (t, J = 7.4 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 202.60, 169.02, 160.95, 160.51, 
137.30, 124.61, 118.30, 111.85, 111.68, 75.22, 73.52, 61.67, 54.94, 53.42, 51.40, 40.20, 38.59, 
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35.13, 23.92, 21.29, 19.41, 13.06. HRMS calcd for C22H28N2O4 (MH+), 385.2127; found 
385.2120. 
(E)-Methyl-2-((1'S,6'S,7'S)-4-cyano-6'-ethyl-3-oxo-3',5',6',7',8',8a'-hexahydro-2'H-
spiro[indoline-2,1'-indolizine]-7'-yl)-3-methoxyacrylate (9-Cyano corynantheidine 
pseudoindoxyl,  7): 5 (20 mg, 0.038 mmol) was dissolved in dry DMF (500 uL) in a sealed tube, 
Pd(PPh3)4 (4.3 mg, 0.1 equiv) and Zn(CN)2 (8.8 mg, 2 equiv) were added. The reaction mixture 
was stirred at 80 °C for 3h. After 3h, the reaction was diluted with EtOAc (20 mL) and washed 
with brine 5 times. The organic layer was dried over Na2SO4 and evaporated under reduced 
pressure. The residue was redissolved in DCM and purified using flash column chromatography 
(gradient: 20-80% EtOAC in hexanes) to yield 10 mg (65%) of 7 as an amorphous brown solid. 
IR (NaCl): 3355, 2940, 2233, 1699, 1606, 1501, 1438, 1242, 993, 859, 1082, 776. 1H NMR (600 
MHz, CDCl3) δ 7.47 – 7.43 (m, 1H), 7.28 (s, 1H), 7.07 (d, J = 8.4 Hz, 1H), 7.05 (d, J = 7.2 Hz, 
1H), 5.43 (s, 1H), 3.68 (s, 3H), 3.62 (s, 3H), 3.15 (t, J = 10.1 Hz, 2H), 2.79 (dt, J = 12.8, 3.5 Hz, 
1H), 2.40 – 2.33 (m, 2H), 2.31 – 2.27 (m, 1H), 2.23 (t, J = 12.1 Hz, 1H), 2.19 – 2.13 (m, 1H), 
1.96 – 1.90 (m, 1H), 1.66 – 1.59 (m, 1H), 1.51 (d, J = 11.2 Hz, 1H), 1.23 – 1.16 (m, 1H), 1.07 (d, 
J = 12.7 Hz, 1H), 0.85 (t, J = 7.4 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 201.47, 169.06, 
162.01, 160.51, 142.35, 137.85, 136.72, 129.43, 128.16, 127.88, 120.06, 111.79, 110.73, 75.10, 
73.89, 61.70, 55.07, 53.59, 51.40, 40.28, 38.57, 36.87, 36.86, 35.53, 24.92, 24.08, 19.48, 13.08. 
HRMS calcd for C23H27N3O4 (MH+), 410.2080; found 410.2068. 
(E)-Methyl-2-((1'S,6'S,7'S)-6'-ethyl-3-oxo-4-phenyl-3',5',6',7',8',8a'-hexahydro-2'H-
spiro[indoline-2,1'-indolizine]-7'-yl)-3-methoxyacrylate (9-Phenyl corynantheidine 
pseudoindoxyl, 8): 5 (75 mg, 0.14 mmol) was dissolved in dry toluene (0.5 mL) and the solvent 
was removed under reduced pressure to ensure azeotropic removal of water residues. Dry 
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methanol (1 mL) and dry toluene (1.5 mL) were added. To the resulting solution were added 
phenylboronic acid (19 mg, 1.1 equiv), K2CO3 (38.9 mg, 2 equiv) and Pd(PPh3)4 (8.1 mg, 0.05 
equiv). The mixture was stirred at 80 °C for 2 hrs. The solvent was evaporated under reduced 
pressure and the residue suspended in DCM, rinsed with water and brine (20 mL), then the 
organic layer was dried over Na2SO4 and was evaporated. Purified using flash column 
chromatography (gradient: 20-50% EtOAc in hexanes) to yield: 21 mg (32%) of 8 as a yellow 
amorphous solid. IR (NaCl): 3364, 2936, 2360, 1698, 1600, 1483, 1436, 1233, 1150, 759. 1H 
NMR (600 MHz, CDCl3) δ 7.52 – 7.49 (m, 2H), 7.43 – 7.34 (m, 4H), 7.30 (s, 1H), 6.82 (d, J = 
8.2 Hz, 1H), 6.68 (d, J = 7.3 Hz, 1H), 5.26 (s, 1H), 3.69 (s, 3H), 3.63 (s, 3H), 3.15 (d, J = 10.0 
Hz, 2H), 2.79 (dt, J = 13.0, 3.3 Hz, 1H), 2.34 – 2.25 (m, 3H), 2.21 (s, 1H), 2.17 – 2.10 (m, 1H), 
1.95 – 1.88 (m, 1H), 1.69 – 1.63 (m, 1H), 1.53 – 1.47 (m, 1H), 1.24 – 1.18 (m, 1H), 1.14 – 1.09 
(m, 1H), 0.86 (t, J = 7.4 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 201.47, 169.06, 162.01, 160.51, 
142.35, 137.85, 136.72, 129.43, 128.16, 127.88, 120.06, 111.79, 110.73, 75.10, 73.89, 61.70, 
55.07, 53.59, 51.40, 40.28, 38.57, 36.87, 36.86, 35.53, 24.92, 24.08, 19.48, 13.08. HRMS calcd 
for C28H32N2O4 (MH+), 461.2440; found 461.2422. 
(E)-Methyl-2-((1'S,6'S,7'S)-6'-ethyl-4-(furan-3-yl)-3-oxo-3',5',6',7',8',8a'-hexahydro-2'H-
spiro[indoline-2,1'-indolizine]-7'-yl)-3-methoxyacrylate (9-Furyl corynantheidine 
pseudoindoxyl, 9): The procedure described for the synthesis of 8 was used. Instead of 
phenylboronic acid, (furan-3-yl)boronic acid was employed. Yield: 81%. Compound 9 is a bright 
yellow amorphous powder. IR (NaCl): 3358, 2954, 2795, 2360, 2341, 1691, 1604, 1437, 1316, 
1238, 1152, 796, 772. 1H NMR (600 MHz, Chloroform-d) δ 8.49 (d, J = 1.4 Hz, 1H), 7.48 (d, J = 
1.7 Hz, 1H), 7.40 (t, J = 7.8 Hz, 1H), 7.31 (s, 1H), 6.87 (d, J = 7.5 Hz, 1H), 6.84 (dd, J = 1.9, 0.9 
Hz, 1H), 6.77 (d, J = 8.1 Hz, 1H), 5.22 (s, 1H), 3.70 (s, 3H), 3.65 (s, 3H), 3.22 – 3.14 (m, 2H), 
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2.81 (dt, J = 12.6, 3.7 Hz, 1H), 2.40 – 2.32 (m, 2H), 2.32 – 2.22 (m, 2H), 2.17 (dd, J = 11.5, 3.2 
Hz, 1H), 2.00 – 1.92 (m, 1H), 1.75 – 1.65 (m, 1H), 1.57 – 1.51 (m, 1H), 1.23 (dtd, J = 15.1, 7.4, 
2.7 Hz, 1H), 1.15 – 1.10 (m, 1H), 0.89 (t, J = 7.4 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 
201.73, 169.03, 162.40, 160.45, 143.85, 142.48, 137.00, 132.42, 122.74, 118.06, 116.66, 111.77, 
110.60, 110.18, 75.11, 74.00, 61.65, 55.07, 53.54, 51.38, 40.28, 38.61, 35.68, 24.01, 19.50, 
13.11. HRMS calcd for C26H30N2O5 (MH+), 451.2433; found 451.2215. 
(E)-Methyl-2-((1'S,6'S,7'S)-4-acetoxy-6'-ethyl-3-oxo-3',5',6',7',8',8a'-hexahydro-2'H-
spiro[indoline-2,1'-indolizine]-7'-yl)-3-methoxyacrylate (9-O-Acetyl corynantheidine 
pseudoindoxyl, 10): 4 (20 mg, 0.05 mmol) was dissolved in pyridine (0.5 mL) and acetic 
anhydride (80 uL) was added. The mixture was stirred at rt for 2h. The solution was poured into 
sat. aqueous NaHCO3 solution and extracted with DCM (30 mL). The organic layer was 
separated, rinsed with brine (10 mL), dried over Na2SO4 and evaporated under reduced pressure 
the residue was redissolved in DCM and purified using flash column chromatography (gradient: 
0-5% MeOH in DCM) to yield 13 mg (59%) of 10 as a bright yellow amorphous solid. IR 
(NaCl): 3393, 2956, 2874, 2787, 1761, 1688, 1628, 1503, 1239, 1217, 910, 764. 1H NMR (500 
MHz, Chloroform-d) δ 7.38 (t, J = 8.0 Hz, 1H), 7.28 (s, 1H), 6.71 (d, J = 8.2 Hz, 1H), 6.36 (d, J 
= 7.6 Hz, 1H), 5.73 (s, 1H), 3.68 (s, 3H), 3.62 (s, 3H), 3.20 (dd, J = 8.6, 3.0 Hz, 2H), 2.79 (dd, J 
= 12.6, 3.9 Hz, 1H), 2.36 (s, 3H), 2.33 – 2.22 (m, 3H), 2.22 – 2.14 (m, 1H), 1.95 (dt, J = 15.8, 
6.3 Hz, 1H), 1.63 (dt, J = 13.0, 6.1 Hz, 1H), 1.53 (d, J = 11.6 Hz, 1H), 1.30 – 1.16 (m, 2H), 1.16 
– 1.09 (m, 1H), 0.86 (t, J = 7.3 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 199.57, 169.14, 168.98, 
161.57, 160.47, 148.07, 138.28, 113.07, 111.70, 110.70, 109.35, 75.71, 73.70, 61.67, 55.02, 
53.49, 51.38, 40.25, 38.51, 35.16, 23.91, 21.01, 19.49, 13.08. HRMS calcd for C24H30N2O6 
(MH+), 443.2182; found 443.2174. 
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(E)-Methyl 2-((1'S,6'S,7'S)-1-benzyl-6'-ethyl-4-methoxy-3-oxo-3',5',6',7',8',8a'-hexahydro-
2'H-spiro[indoline-2,1'-indolizine]-7'-yl)-3-methoxyacrylate (N-Benzyl mitragynine 
pseudoindoxyl, 11): Compound 3 was dissolved in dry acetonitrile (0.5 mL) and NaH (6 mg, 10 
equiv) was added. The resulting suspension was stirred at rt for 30 minutes, during which its 
color turned red. Benzyl bromide (7.2 uL, 2.5 equiv) was added and the mixture stirred for 2h at 
rt. The red color disappeared promptly after the addition of benzyl bromide. After the reaction 
time, the mixture was carefully poured into cold water (20 mL) and extracted with DCM (30 
mL). The organic layer was rinsed with brine (5 mL) separated, dried over Na2SO4 and 
evaporated under reduced pressure. The residue was redissolved in DCM and purified using flash 
column chromatography (gradient: 0-5 % MeOH in DCM) to yield: 7.8 mg (64 %) of 11 as a 
bright yellow amorphous solid. IR (NaCl): 2940, 2794, 1694, 1610, 1497, 1337, 1265, 1239, 
1078, 732. 1H NMR (500 MHz, Chloroform-d) δ 7.42 – 7.28 (multiple overlapping peaks, 5H), 
7.25 – 7.17 (multiple overlapping peaks, 2H), 6.08 (d, J = 8.1 Hz, 1H), 6.04 (d, J = 8.3 Hz, 1H), 
5.35 (d, J = 17.4 Hz, 1H), 4.73 (d, J = 17.3 Hz, 1H), 3.90 (s, 3H), 3.70 (s, 3H), 3.64 (s, 3H), 3.13 
(dd, J = 11.1, 2.2 Hz, 1H), 3.02 (t, J = 8.1 Hz, 1H), 2.78 – 2.72 (m, 1H), 2.33 – 2.18 (m, 4H), 
2.09 – 2.02 (m, 1H), 1.94 (dt, J = 13.7, 8.5 Hz, 1H), 1.66 (dt, J = 19.2, 6.8 Hz, 1H), 1.50 (d, J = 
10.9 Hz, 1H),, 1.13 (d, J = 11.8 Hz, 1H), 0.86 (t, J = 7.4 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 
199.55, 169.06, 161.60, 160.40, 158.81, 138.88, 138.82, 129.25, 129.02, 128.76, 128.64, 126.95, 
126.51, 111.99, 108.49, 101.82, 98.07, 61.63, 55.89, 55.23, 53.92, 51.38, 47.61, 40.46, 38.67, 
33.80, 32.06, 24.18, 19.82, 13.13. HRMS calcd for C30H36N2O5 (MH+), 505.2702; found 
505.2726. 
(E)-Methyl 2-((1'S,6'S,7'S)-6'-ethyl-4-methoxy-1-methyl-3-oxo-3',5',6',7',8',8a'-hexahydro-
2'H-spiro[indoline-2,1'-indolizine]-7'-yl)-3-methoxyacrylate (N-Methyl mitragynine 
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pseudoindoxyl, 12): The procedure described for the synthesis of 11 was used. Instead of benzyl 
bromide, iodomethane was employed. Yield: 58%. Compound 12 is a bright yellow amorphous 
powder. IR (NaCl): 2947, 2778, 2361, 1687, 1611, 1500, 1337, 1273. 1H NMR (600 MHz, 
Chloroform-d) δ 7.34 (t, J = 8.1 Hz, 1H), 7.28 (s, 1H), 6.25 (d, J = 8.2 Hz, 1H), 6.05 (d, J = 8.0 
Hz, 1H), 3.88 (s, 3H), 3.69 (s, 3H), 3.62 (s, 3H), 3.17 (s, 3H), 3.16 – 3.10 (m, 2H), 2.74 (dt, J = 
13.0, 3.7 Hz, 1H), 2.34 (q, J = 8.9 Hz, 1H), 2.26 (dd, J = 11.3, 2.6 Hz, 1H), 2.21 – 2.12 (m, 2H), 
2.08 – 2.03 (m, 1H), 1.92 (dt, J = 13.8, 8.7 Hz, 1H), 1.69 – 1.62 (m, 1H), 1.48 (dt, J = 11.1, 3.1 
Hz, 1H), 1.28 – 1.23 (m, 1H), 1.20 (ddd, J = 13.3, 7.6, 2.8 Hz, 1H), 1.08 (dt, J = 13.0, 3.1 Hz, 
1H), 0.84 (t, J = 7.4 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 199.87, 169.08, 162.01, 160.36, 
158.90, 139.01, 112.04, 108.08, 100.37, 97.46, 78.27, 74.62, 61.59, 55.86, 55.14, 53.88, 51.34, 
40.54, 38.72, 31.99, 30.02, 24.29, 19.71, 13.17. HRMS calcd for C24H32N2O5 (MH+), 429.2389; 
found 429.2393. 
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Abbreviations Used: 
%MPE – percent maximal effect; 6TM – six transmembrane; 7TM – seven transmembrane; 
CHO – Chinese hamster ovary; CPA – conditioned place aversion; CPP – conditioned place 
preference; DAMGO – [D-Ala2, N-MePhe4, Gly-ol5]-enkephalin; DCM – dichloromethane; 
DMF – N,N-dimethylformamide; DOR-1  – a delta opioid receptor (Oprd1) clone; DPDPE –  [D-
Pen2,D-Pen5]Enkephalin; dppp - 1,3-bis(diphenylphosphino)propane; GDP – guanosine 
diphosphate; KO – knockout; KOR-1  – a kappa opioid receptor (Oprk1) clone; MOR-1 – a mu 
opioid receptor (Oprm1) clone; norBNI – norbinaltorphimine; NTI – naltrindole; PIFA – 
[bis(trifluoroacetoxy)iodo]benzene. 
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TABLES 
Table 1. Receptor affinities and subcutaneous antinociception in mice. 
  Affinity (Ki nM)
a Antinociception 
Compound MOR-1 KOR-1 DOR-1 scb 
        mg/kg (CI) 
1 230 ± 47 231 ± 21 1011 ± 49 166 (101-283) 
2 37 ± 4 132 ± 7 91 ± 8 0.46 (0.39-0.71) 
3 0.8 ± 0.2 24 ± 0.9 3.0 ± 1.3 0.76 (0.56-0.83) 
4 1.4 ± 0.2 170 ± 61 6.1 ± 1.1 0.18 (0.16-0.20) 
6 0.46 ± 0.01 19 ± 4.7 2.9 ± 0.29 0.24 (0.20-0.26) 
7 0.5 ± 0.01 47 ± 3.3 2.4 ± 0.3 0.32 (0.26-0.41) 
8 0.91 ± 0.06 51 ± 9.7 0.8 ± 0.13 1.0 (0.70-1.35) 
9 0.94 ± 0.02 39 ± 11 1.5 ± 0.37 1.1 (0.83-1.38) 
10 2.5 ± 0.6 31 ± 14 20 ± 1 0.38 (0.29-0.49) 
11 249 ± 41 136 ± 8 258 ± 34 - 
12 375 ± 138  >1000  >1000 - 
DAMGO 3.3 ± 0.43c - - - 
U50,488H - 0.73 ± 0.32c - - 
DPDPE - - 1.39 ± 0.67c - 
NTI - - 0.46 ± 0.32c - 
norBNI - 0.23 ± 0.03c - - 
morphine 4.6 ± 1.8c - - 2.5(1.8, 3.4) 
aCompetition studies were performed with the indicated compounds against 125I-IBNtxA 
(0.1 nM) in membranes from CHO cells stably expressing the indicated cloned mouse 
opioid receptors. Results are presented as nM ± SEM from 3 independent experiments 
performed in triplicate. bCumulative dose−response curves were carried out on groups of 
CD1 mice (n = 10) using radiant heat tail-flick assays with indicated compound at the 
indicated doses (sc), and antinociception was tested 15 min later at peak effect. Results 
from two independent experiments are shown as mean (95% Cl). cValues from the 
literature.78 "-" Denotes not determined or not applicable. 
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Table 2. [35S]GTPγS functional assays in transfected cell lines.  
  [35S]GTPγS functional assaysa  
Compound MOR-1 KOR-1 DOR-1 
  EC50 (nM) Emax (%) EC50 (nM) IC50 (nM) EC50 (nM) IC50 (nM) 
1 203 ± 13 65 ± 2.8 - >4 uM - >4 uM 
2 53 ± 4 77 ± 5 - 2524 ± 552 - 691 ± 434 
3 1.7 ± 0.1 84 ± 5 - 31 ± 3 - 61 ± 6 
4 2.0 ± 0.1 124 ± 2 - - - 293 ± 129 
6 1.4 ± 0.03 116 ± 2 - 252 ± 48 - 193 ± 48 
7 0.7 ± 0.2 122 ± 2 - 721 ± 58 - 73 ± 3 
8 1.4 ± 0.25 123 ± 5 - 171 ± 10 0.83 ± 0.37 (89 ± 3)b - 
9 1.5 ± 0.3 100 ± 1 - 202 ± 14 - 39 ± 5 
10 3.9 ± 0.5 120 ± 6 - - - - 
11 - - - - - - 
12 - - - - - - 
DAMGO 19 ± 7 - - - - - 
U50,488H - - 17 ± 6.1 - - - 
DPDPE - - - - 10 ± 2.2 - 
NTI - - - - - 0.72 ± 0.11 
norBNI - - - 2.9 ± 0.14 - - 
aEfficacy data were obtained using agonist induced stimulation of [35S]GTPγS binding assay. Efficacy is 
represented as EC50 (nM) and percent maximal stimulation (Emax) relative to standard agonist DAMGO (MOR-
1), DPDPE (DOR-1), or U50,488H (KOR-1) at 1000 nM. To determine the antagonist properties of a 
compound, membranes were incubated with 100 nM of the appropriate agonist in the presence of varying 
concentrations of the compound bCompound 8 is an agonist at DOR-1. Results are presented as nM ± SEM from 
3 independent experiments performed in triplicate.  "-" Denotes not determined or not applicable. 
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 Table 3. In vitro and in silico binding affinities and specific contacts of mitragynine and derivatives. 
  
Cmpd 
In vitro Ki 
(nM) 
in silico 
Ki (nM) 
non-
specifica 
in silico 
Ki (nM) 
specificb 
receptor side chains in polar contact with 
the ligand 
receptor side chains in non-polar contact 
with the ligand 
Mu 
1 230 ± 47 23 569 Gln124, Tyr128, Asp147, Tyr326 Met151, Trp293, Ile296, Ile322 
2 37 ± 4 4.0 55 Asp147, Lys233, Trp293 Tyr148, Met151, Leu219, Leu232, Ile296 
3 0.75 ± 0.18 2.5 2.5 Asp147, Tyr148, Lys233 Ile144, Leu219, Leu232, Trp293, Ile296, His297 
Delta 
 
1 
 
1011 ± 49 
 
159 
 
1565 
 
Gln105, Lys108, Asp128, Tyr129, Tyr129 
 
Leu128, Lys214 (aliphatic chain), Val217 
2 90 ± 8 19 19 Asp128, Tyr129 
 
Met132, Lys214 (aliphatic chain), Val217, 
Trp274, Ile277, Ile304 
3 3 ± 1.3 17 17 Asp128, Tyr129 
 
Met132, Lys214 (aliphatic chain), Val217, 
Trp274, Ile277, Val281 
Kappa 
1 231 ± 21 17 69 Asp138, Tyr139, Ser211 Trp124, Val134,  Leu135 
2 131 ± 7 8.3 53 Thr111, Asp138, Tyr139, Lys227, Tyr312, Tyr320 Gln115, Leu135, Ile294 
3 24 ± 9 3.2 23 Gln115, Asp138, Tyr139, Ser211, Tyr312 Phe114, Val118, Ile294, Ile316 
aInhibitory constants calculated for the lowest energy docked complexes including non-specifically bound poses. bInhibitory constants calculated for 
the lowest energy docked complexes excluding low energy poses which were regarded as false positives. 
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FIGURE CAPTIONS 
Figure 1. Structure of several important opioid natural product analogs. 
Figure 2. Structure of the studied mitragynine analogs. 
Scheme 1. Synthesis of mitragynine derivatives 2-12. 
Reagents and conditions: (a) PIFA, H2O, acetonitrile, 0 °C, 1h; (b) Zn(OTf)2, toluene, 110 °C, 
2h; (c) AlCl3, EtSH, DCM, 0 °C, 5h; (d) Tf2O, pyridine, DCM, -40 °C, 1h; (e, yielding 6) 
Pd(OAc)2, dppp, HCOOH, DMF, 60 °C, 1h; (f, yielding 7) Zn(CN)2, Pd(PPh3)4, DMF, 80 °C, 
2h; (g, yielding 8 and 9) phenylboronic acid (8) or 3-furanylboronic acid (9), Pd(PPh3)4, K2CO3, 
MeOH, toluene, 80 °C, 2h; (h) Ac2O, pyridine, rt, 1h; (i, yielding 11 and 12) benzyl bromide 
(11) or iodomethane (12), NaH, acetonitrile, rt, 2h. 
Figure 3. β-arrestin-2 recruitment and antagonism of β-arrestin-2 recruitment. 
A) β-arrestin-2 recruitment: β-arrestin-2 recruitment was determined using the DiscoveRx 
PathHunter enzyme complementation assay using modified MOR-1 in CHO cells. Compounds 
were found to be completely G-protein biased. B) Antagonism of β-arrestin-2 recruitment: The 
same cells were incubated with the antagonist (2, 3) for 30 minutes at 37 °C prior to the addition 
of agonist (10µM DAMGO) at MOR-1.  Compounds 2 and 3 were able to antagonize β-arrestin-
2 recruitment by DAMGO. IC50 values: 2:  725 ± 292 nM; 3: 34 ± 2 nM  
Figure 4. Antinociception of compound 3 upon intracerebroventricular, subcutaneous, and oral 
administration. 
A) Dose-response curves of antinociception of 3 and morphine given supraspinally in CD1 mice. 
Two independent determinations of the cumulative dose–response curves were performed on 
groups of mice (n = 5) for antinociception in the tail flick assay with 3 intracerebroventricularly. 
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Animals were tested 15 min later at peak effect to generate the analgesic dose-response curve. 
Each point represents mean ± SEM for 10 mice. ED50 values (and 95% CI) were 0.38 (0.18- 
0.81) µg for 3. B) Dose-response curves of antinociception of 3 given subcutaneously in CD1 
mice. Three independent determinations of the cumulative dose–response curves were performed 
on groups of mice (n = 10) for antinociception in the tail flick assay, 30 mice in total. ED50 (and 
95% CI) = 0.76 (0.56-0.83) mg/kg. C) Time course of tail flick antinociception of 3 given orally 
in CD1 male mice. Groups of mice (n=10) were given different doses of 3 orally by gavage and 
tested for analgesic response at the indicated time points. ED50 (and 95% CI) = 7.5 (4.3-13) 
mg/kg. D) Hot plate. Groups of CD1 mice (n = 10) were assessed for antinociception of 3 at peak 
effect in two independent experiments (n = 20 total) in a cumulative dose-response paradigm. 
Analgesia was determined using a 55 °C hot plate where the latency to respond with a hind paw 
lick or shake/flutter, whichever came first, was recorded. ED50 (and 95% CI) = 0.99 mg/kg 
(0.75–1.3). 
Figure 5. Pharmacological and genetic reversal of antinociception of 3. 
A) Reversal of antinociception by selective antagonists. Groups of CD1 mice (n = 10) received 3 
(1.5 mg/kg sc) and the indicated antagonist. β-Funaltrexamine (β-FNA; 40 mg/kg sc) and 
norbinaltorphimine (norBNI; 10 mg/kg sc) were administered 24 hours before agonist testing. 
Naltrindole (NTI; 0.5 mg/kg sc), naloxone (1 mg/kg), and yohimbine (10 mg/kg) were 
administered 15 minutes before 3. All antinociception testing was performed 15 min after the 
administration of 3. Similar results were observed in two independent replications. 3 
antinociception is insensitive to NTI, norBNI, and yohimbine, whereas antinociception is 
antagonized by β-FNA and naloxone (two-way ANOVA followed by Bonferroni post hoc 
comparisons test, p<0.05). All values are expressed as the mean ± SEM. B) Antisense 
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oligodeoxynucleotide injection: Groups of mice (n=15) received the stated antisense (5-10 µg) or 
mismatch (5-10 µg) oligodeoxynucleotide icv under light isoflurane anesthesia on days 1, 3 and 
5. Tail flick antinociception was tested on day 6. Control groups received no injection prior to 
testing. On test day, mice received 3 (1.5 mg/kg, sc). All experiments were performed 3 times 
with similar results observed with each determination. Analgesic response of 3 was only affected 
in mu receptor downregulated mice (MOR-1 AN)(one-way ANOVA followed by Bonferroni post 
hoc comparisons test). *Significantly different from control (p < 0.05). Data for agonist controls 
is shown in the Supporting Material (Figure S6) and sequences of AN and MIS oligos are shown 
in table 4 (experimental section). C) Antinociception of 3 in wild-type, exon 11 KO, and exon 
1/exon 11 double KO C57 mice. Two independent determinations of the cumulative dose–
response curves were performed on groups of mice (n = 5) for antinociception in the tail flick 
assay with 3 given subcutaneously. Compound 3 displayed similar antinociceptive effects in 
wild-type (ED50 = 0.83 mg/kg (0.37-1.9)) and exon 11 KO mice (ED50 = 1.4 mg/kg (0.34-5.8)), 
however, no antinociception was observed in exon 1/exon 11 double KO mice suggesting that the 
antinociceptive effect of 3 is mediated by the E1 MOR-1 variants. 
Figure 6. Side effect studies with compound 3. 
A) Antinociceptive tolerance: Mice were dosed 2x daily with 2x antinociceptive ED
50
 with either 
morphine or 3 until they showed complete analgesic tolerance. 3 showed very slow onset of 
tolerance compared with morphine. *Significantly different from morphine (p < 0.05). The 
experiment was replicated at least twice with similar results. B) Physical dependence: Groups of 
mice were dosed 2x daily with 2x antinociceptive ED
50
 with morphine or 3. Separate groups of 
mice were used for the 5, 22 and 29-day treatment with 3 and the animals within each group 
were sacrificed following the experiment with naloxone. Animals were challenged with naloxone 
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(1 mg/kg) on day 5 of the morphine group, and days 5, 22, and 29 of the 3 groups. Number of 
jumps was counted over a 15 min period post-injection. The response of mice treated with 3 on 
either day was not significantly greater than that of mice treated with saline. *Significantly 
different from saline. (One-way ANOVA followed by Dunnett’s multiple comparison test, p < 
0.05). C) Gastrointestinal transit. Groups of mice (n = 10) received saline, morphine (5 mg/kg), 
or 3 (1.5 and 4 mg/kg) before receiving an oral dose of 0.2 mL of charcoal meal by gavage. 
Animals were sacrificed 30 min later, and the distance traveled by charcoal was measured. 3 
lowered transit significantly compared with saline (P < 0.05) but less than morphine at both 
doses (P < 0.05) as determined by ANOVA followed by Tukey’s multiple-comparison test. The 
inhibition of gastrointestinal transit seems to plateau even at doses ~five times higher than the 
antinociceptive ED50. D) Respiratory rate. Animals were randomly assigned to receive saline (n 
= 5), 3 (1.2 and 3 mg/kg, sc, n = 5 at each dose), or morphine (5 and 10 mg/kg, n = 5 at each 
dose). While morphine caused respiratory depression at both 2x and 5x antinociceptive ED50 
dose (5 and 10 mg/kg, respectively), 3 did not depress respiratory rate at ~2x antinociceptive 
ED50 dose (1.2 mg/kg) and was not significantly different from saline at any time point, whereas 
morphine (5 mg/kg) decreased respiratory depression in comparison with 3 (p < 0.05) as 
determined by repeated-measures ANOVA followed by Tukey’s multiple-comparison test. 
However, at ~5x antinociceptive ED50 dose (3 mg/kg), 3 showed signs of respiratory depression 
albeit significantly less than the equianalgesic dose of morphine (10 mg/kg) at any given time 
point. (repeated-measures ANOVA followed by Tukey’s multiple-comparison test). E) 
Conditioned place-preference and aversion. Compound 3 alone did not produce conditioned 
place preference or aversion. After determination of initial preconditioning preferences, mice 
were place conditioned daily for 2 days with morphine (10 mg/kg/d, ip), U50,488 (30 mg/kg/d, 
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ip), cocaine (10 mg/kg/d, ip) or 3 (1.3 mg/kg/d, ip and 3.2 mg/kg/d, ip). Mean difference in time 
spent on the drug-paired side ± SEM is presented (n=17-21). *Significantly different from 
matching preconditioning preference (p < 0.05); + significantly different from cocaine, morphine 
and U50,488 preference (two-way repeated measures ANOVA with Sidak’s post hoc test).  
Figure 7. Lowest energy docked complexes of specifically bound mitragynine derivatives (1-3) 
to opioid receptors. 
Binding pocket side chains which were identified in the crystal structures to take part in receptor 
ligand interactions and were kept flexible during docking are shown. Side chains which are in 
direct contact with the ligands are depicted in orange. Non-polar hydrogens are omitted for 
clarity. 
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Figure 2. 
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Scheme 1. 
 
Figure 3. 
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Figure 4. 
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Figure 6.  
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Figure 7.  
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